Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average – What’s Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.53 and traded as high as $4.59. Cumberland Pharmaceuticals shares last traded at $4.40, with a volume of 118,912 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 6th.

Cumberland Pharmaceuticals Trading Down 4.1 %

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The business’s 50 day simple moving average is $4.38 and its 200 day simple moving average is $2.53. The stock has a market cap of $61.46 million, a P/E ratio of -5.71 and a beta of -0.18.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The company had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP boosted its position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 37,649 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,271 shares during the period. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent quarter. Institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.